Rijpkema Mark, Boerman Otto C, Oyen Wim J G
Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Curr Drug Targets. 2015;16(6):625-33. doi: 10.2174/1389450115666141029234200.
Due to their high target affinity and specificity, antibodies are very suitable tumor-targeting vehicles for imaging and therapeutic application. This enables a theranostic approach of imaging targeted drug delivery in oncology and opens the way for personalized medicine, predicting drug delivery, response, and treatment outcome in the individual patient. Of the currently available molecular imaging techniques, single-photon emission computed tomography (SPECT) and positron emission tomography (PET) are the best suited imaging techniques to visualize and determine drug delivery to the target tissue quantitatively. Using the same antibody for imaging and targeted therapy may eliminate some limitations of antibody-based molecular imaging and therapy, like heterogeneous antigen expression and poor accessibility. However, challenges of this approach remain, for example in the pharmacokinetic behavior of radiolabeled antibodies and antibody-drug-conjugates. Despite these challenges, also exciting opportunities are at the horizon, by using antibodies as multimodal vehicles carrying both a diagnostic agent and a therapeutic agent. In this review, both the challenges and the opportunities of using radiolabeled antibodies for image-guided drug delivery are discussed.
由于其高靶向亲和力和特异性，抗体是非常适合用于成像和治疗应用的肿瘤靶向载体。这使得在肿瘤学中采用成像引导靶向药物递送的诊疗方法成为可能，并为个性化医疗开辟了道路，能够预测个体患者的药物递送、反应和治疗结果。在目前可用的分子成像技术中，单光子发射计算机断层扫描（SPECT）和正电子发射断层扫描（PET）是最适合用于可视化和定量确定药物向靶组织递送情况的成像技术。使用相同的抗体进行成像和靶向治疗可能会消除基于抗体的分子成像和治疗的一些局限性，如异质性抗原表达和可及性差等问题。然而，这种方法仍面临挑战，例如放射性标记抗体和抗体 - 药物偶联物的药代动力学行为。尽管存在这些挑战，但通过将抗体用作携带诊断剂和治疗剂的多模态载体，令人兴奋的机遇也即将出现。在本综述中，将讨论使用放射性标记抗体进行图像引导药物递送所面临的挑战和机遇。
